Frontier Capital Management’s Moderna MRNA Stock Holding History

Frontier Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-140,948	Closed	-$16.7M	–	273
2022 Q3	$16.7M	Sell	140,948 -7,407	-5%	-$1.12M	0.2%	161
2022 Q2	$21.2M	Buy	148,355 +1,066	+0.7%	+$152K	0.24%	147
2022 Q1	$25.4M	Buy	+147,289	New	+$24.8M	0.23%	146
2021 Q4	–	Sell	-97,098	Closed	-$37.4M	–	278
2021 Q3	$37.4M	Sell	97,098 -367,042	-79%	-$135M	0.29%	123
2021 Q2	$109M	Sell	464,140 -181,164	-28%	-$32.4M	0.8%	30
2021 Q1	$84.5M	Buy	645,304 +224,909	+53%	+$32.6M	0.64%	47
2020 Q4	$43.9M	Sell	420,395 -31,552	-7%	-$3.19M	0.33%	121
2020 Q3	$32M	Sell	451,947 -87,013	-16%	-$6.07M	0.28%	126
2020 Q2	$34.6M	Buy	538,960 +72,937	+16%	+$3.99M	0.31%	117
2020 Q1	$14M	Buy	+466,023	New	+$10.7M	0.16%	166

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Frontier Capital Management's MRNA Position: Q4 2022 in Review

Frontier Capital Management sold out of Moderna (MRNA) in Q4 2022, closing a stake of 140,948 shares — an estimated $16.7M sold.

Frontier Capital Management first reported a position in MRNA in Q1 2020 and held it in 10 quarters. The position peaked at $109M in Q2 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

Frontier Capital Management reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
Frontier Capital Management sold 140,948 Moderna shares in Q4 2022, an estimated $16.7M.
Frontier Capital Management first reported a position in Moderna in Q1 2020 and held it in 10 quarters.
Frontier Capital Management's Moderna position peaked at $109M in Q2 2021.
1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Frontier Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.